Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology

Muscle and Nerve

Volumn 20, Issue SUPPL. 6, 1997, Pages

  Brin, Mitchell F ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse effects; Antibody mediated resistance; Botulinum toxin (BTX); Mouse lethality assay; Zinc endopeptidase

Indexed keywords

ANTIPARKINSON AGENT; BOTULINUM TOXIN;

ANIMAL; CHEMISTRY; HUMAN; IMMUNOLOGY; NEUROMUSCULAR DISEASE; REVIEW;

ANIMALS; ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; HUMANS; NEUROMUSCULAR DISEASES;

EID: 33748271738     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-4598(1997)6+<146::aid-mus10>3.3.co;2-f     Document Type: Article

References (154)

1. Alderson K, Holds JB, Anderson RL: Botulinum induced alteration of nerve muscle interactions in the human orbicularis oculi following treatment for blepharospasm. Neurology 1991; 41:1800-1805.
2. American Academy of Neurology: Assessment: the clinical usefulness of botulinum toxin A in treating neurologic disorders. Report of the Therapeutics and Technology subcommittee of the American Academy of Neurology. [Review]. Neurology 1990; 40:1332-1336.
3. American Academy of Neurology (Therapeutics and Technology Assessment Subcommittee): Training guidelines for the use of botulinum toxin for the treatment of neurologic disorders. Neurology 1994; 44:2401-2403.
4. American Academy of Opthamology Statement: Botulinum A toxin for ocular muscle disorders [editorial]. Lancet 1986; 1:76-77.
5. American Academy of Opthamology Statement: Botulinum toxin therapy of eye muscle disorders. Safety and effectiveness. American Academy of Ophthalmology. Ophthalmology 1989; Part 2 (Sept): 37-41.
6. American Academy of Otolaryngology: Position statement on the clinical usefulness of botulinum toxin in the treatment of spasmodic dysphonia. Arch Otolaryngol Head Neck Surg 1990; 9:8.
7. Anderson TJ, Rivest J, Stell R, Steiger MJ, Cohen H, Thompson PD, Marsden CD: Botulinum toxin treatment of spasmodic torticollis. J R Soc Med 1992; 85:524-529.
8. Ansved T, Odergren T, Borg K: Muscle fiber atrophy in leg muscles after botulinum toxin type A treatment of cervical dystonia. Neurology 1997; 48:1440-1442.
9. Aoki R: Personal communication to Mitchell F. Brin, M.D., 1997.
10. Argov Z, Mastaglia FL: Disorders of neuromuscular transmission caused by drugs. N Engl J Med 1979; 301:409-413.
11. Athena Diagnostics Botulinum Toxin Type A Antibody Test, Athena Diagnostics, Inc., Worcester, MA.
12. Australasian Faculty of Rehabilitative Medicine, Royal Australasian College of Physicians, 145 Macquarie St., Sydney NSW 2000, Australia, 1997.
13. Australian Association of Neurologists, Department of Neurology, Westmead Hospital, NSW 2145, Australia, 1997.
14. Bakheit AM, Ward CD, McLellan DL: Generalised botulism-like syndrome after intramuscular injections of botuinum toxin type A: a report of two cases [letter]. J Neurol Neumsurg Psychiatry 1997; 62:198.
15. Barmaga M: Secrets of secretion revealed. Science 1993; 260:487-489.
16. Biglan AW Gonnering R, Lockhart LB, Rabin B, Fuerste FH: Absence of antibody production in patients treated with botulinum A toxin. Am J Ophthalmol 1986; 101:232-235.
17. Binz T, Kurazono H, Wille M, Frevert J, Wernars K, Niemann H: The complete sequence of botulinum neurotoxin type A and comparison with other clostridial neurotoxins. J Biol Chem 1990; 265:9153-9158.
18. Black JD, Dolly JO: Interaction of 125-I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves. J Cell Biol1986; 103:521-534.
19. Black JD, Dolly JO: Interaction of 125-I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor mediated endocytosis. J Cell Biol 1986; 103:535-544.
20. Black JD, Dolly JO: Selective location of acceptors for botulinum neurotoxin A in the central and peripheral nervous systems. Neuroscience 1987; 23:767-779.
21. Blasi J, Chapman ER, Yamasaki S, Binz T, Niemann H, Jahn R: Botulinum neurotoxin Cl blocks neurotransmitter release by means of cleaving HPC 1/syntaxin. EMBOJ 1993; 12:4821-4828.
22. Blitzer A, Binder WJ, Aviv JE, Keen MS, Brin MF: The management of hyperfunctional facial lines with botulinum toxin: a collaborative study of 210 injection sites in 162 patients. Arch Otolaryngol Head Neck Surg 1997; 123:389-392.
23. Blitzer A, Brin MF, Fahn S, Lange D, Lovelace RE: Botulinum toxin (BOTOX) for the treatment of "spastic dysphonia" as part of a trial of toxin injections for the treatment of other cranial dystonias [letter]. Laryngoscope 1986; 96:1300-1301.
24. Borodic GE, Cozzolino D: Blepharospasm and its treatment, with emphasis on the use of botulinum toxin. Plast Reconstr Surg 1989; 83:546-554.
25. Borodic GE, Ferrante R: Effects of repeated botulinum toxin injections on orbicularis oculi muscle. J Clin Neuroophthalmol 1992; 12:121-127.
26. Borodic GE, Ferrante R, Pearce LB, Smith K: Histologie assessment of dose related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov Disord 1994; 9:31-39.
27. Borodic GE, Pearce LB, Smith K, Joseph M: Botulinum A toxin for spasmodic torticollis: multiple vs. single injection points per muscle. Head Neck 1992; 14:33-37.
28. Boyd RN, Britton TC, Robinson RO, Borzyskowski M: Transient urinary incontinence after botulinum A toxin [letter]. Lancet 1996; 348:481-482.
29. Brin MF, Blitzer A: Botulinum toxin: dangerous terminology errors [letter]. J R Soc Med 1993; 86:493-494.
30. Brin MF, Blitzer A, Stewart C, Pine ZM, Borg Stein J, Miller J, Viswanath NS, Rosenfield DB: Disorders with Excessive Muscle Contraction: Candidates for Treatment with Intramuscular Botulinum Toxin ("botox"), in DasGupta BR (ed): Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects. New York, Plenum, 1993, pp 559-576.
31. Brin MF, Fahn S, Moskowitz CB, Blitzer A, Friedman A, Shale HM, Greene PE, List T, Lovelace RE: Injections of botulinum toxin for the treatment of focal dystonia. Neurology 1986; 36 (Suppl 1):120(Abstract).
32. Calderon Gonzalez R, Calderon Sepulveda RF, Rinconreyes M, Garciaramirez J, Minoarango E: Botulinum toxin A in management of cerebral palsy. Pediat Neurol 1994; 10:284-288.
33. Campbell K, Collins MD, East AK: Nudeotide sequence of the gene coding for Clostridium botulinum (Clostndium argentinense) type G: neurotoxin genealogical comparison with other clostridial neurotoxins. Biochim Biophys Acta 1993; 1216:487-491.
34. Campbell KD, Collins MD, East AK: Gene probes for identification of the botulinal neurotoxin gene and specific identification of neurotoxin type B, type E, and type F. J Clin Microbiol 1993; 31:2255-2262.
35. Chutorian A, Root L: Management of spasticity in children with botulinum A toxin. Intl Pediatr 1994; 9:129-137
36. Chutorian A, Root L, BTA Study Group: A multi-centered, randomized, double-blind, placebo-controlled trial of botulinum toxin type A in the treatment of lower limb spasticity in pediatric cerebral palsy. Mov Disord 1995; 10:364(Abstract).
37. Claus D, Druschky A, Erbguth F: Botulinum toxin: influence on respiratory heart rate variation. Mov Disord 1995; 10:574-579.
38. Corry IS, Cosgrove AP, Duffy CM, McNeill S, Taylor TC, Graham HK: Botulinum toxin A as an alternative to serial casting in the conservative management of equinus in cerebral palsy. Child Neurology 1995; 37:20(Abstract).
39. Corry IS, Cosgrove AP, Walsh EG, McClean D, Graham HK: Botulinum toxin A in the hemiplegic upper limb: a double-blind trial. Dev Med Child Neurol 1997; 39:185-193.
40. Cosgrove AP, Corry IS, Graham HK: Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 1994; 36:386-396.
41. Cosgrove AP, Graham HK: Botulinum toxin A in the management of spasticity with cerebral palsy. Br J Surg 1992; 74; 136.
42. DasGupta BR: Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects. New York, Plenum, 1993.
43. DasGupta BR: Structures of Botulinum Neurotoxin, Its Functional Domains, and Perspectives on the Crystalline Type A Toxin, in Jankovic J, Hallett M (eds): Therapy with Botulinum Toxin. New York, Marcel Dekker, 1994, pp 15-39.
44. DasGupta BR, Tepp W: Protease activity of botulinum neurotoxin type E and its light chain: cleavage of actin. Biochem Biophys Res Commun 1993; 190:470-474.
45. Denislic M, Meh D: Botulinum toxin in the treatment of cerebral palsy. Neuropediatrics 1995; 26:249-252.
46. Dezfulian M, Bitar R, Bartlett J: Kinetics study of immunological response to Clostridium botulinum toxin. J Clin Microbiol 1987; 25:1336-1337.
47. Dezfulian M, Hatheway C, Yolken R, Bartlett J: Enzyme-linked immunosorbent assay for detection of Clostndium botulinum type A and type B toxins in stool samples of infants with botulism. J CHn Microbiol 1984; 20:379-383.
48. Doellgast GJ, Beard GA, Bottoms JD, Mheng T, Roh BH, Roman MG, Hall PA, Triscott MX: Enzyme-linked immunosorbent assay and enzyme-linked-coagulation assay for detection of Closiridium botulinum neurotoxin A, neurotoxin B, and neurotoxin E and solution phase complexes with dual label antibodies. J Clin Microbiol 1994; 32:105-111.
49. Doellgast GJ, Brown JE, Koufman JA, Hatheway CE: Sensitive assay for measurement of antibodies to Clostndium botulinum neurotoxins A, B, and E: use of hapten-labeled-antibody elution to isolate specific complexes. J Clin Microbiol 1997; 35:570-583.
50. Doellgast GJ, Triscott MX, Beard GA, Bottoms JD, Cheng T, Roh BH, Roman MG, Hall PA, Brown JE: Sensitive enzyme-linked immunosorbent assay for detection of Clostndium botulinum neurotoxins A, B, and E using signal amplification via enzyme-linked coagulation assay. J Clin Microbiol 1993; 31:2402-2409.
51. Dolly JO: General Properties and Cellular Mechanisms of Neurotoxins, in Jankovic J, Hallett M (eds): Therapy with Botulinum Toxin. New York, Marcel Dekker, 1994.
52. Dolly JO, Ashton AC, McInnes C, Wadsworth JD, Poulain B, Tauc L, Shone CC, Melling J: Clues to the multi-phasic inhibitory action of botulinum neurotoxins on release of transmitters. J Physiol 1990; 84:237-246.
53. East AK, Collins MD: Conserved structure of genes encoding components of botulinum neurotoxin complex M and the sequence of the gene coding for the nontoxic component in nonproteolytic Clostridium botulinum type F. Curr Microbiol 1994; 29:69-77.
54. East AK, Richardson PT, Allaway D, Collins MD, Roberts TA, Thompson DE: Sequence of the gene encoding type F neurotoxin of Clostridium botulinum. FEMS Micmbiol Lett 1992; 96:225-230.
55. Eleopra R, Tugnoli V, Rossetto O, Montecucco C, De Grandis D: Botulinum neurotoxin serotype C: a novel, effective botulinum toxin therapy in humans. Neurosa Lett 1997; 224:91-94.
56. Emerson J: Botulinum toxin for spasmodic torticollis in a patient with myasthema gravis. Mov Disord 1994; 9:367.
57. Erbguth F, Claus D, Engelhardt A, Dressler D: Systemic effect of local botulinum toxin injections unmasks subclinical Lambert-Eaton myasthénie syndrome. J Neurol Neurosurg Psychiatiy 1993; 56:1235-1236.
58. Girlanda P, Vita G, Nicolosi C: Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatiy 1992; 55:844-845.
59. Glanzman RE, Gelb DJ, Drury I, Bromberg MB, Truong DD: Brachial plexopathy after botulinum toxin injections. Neurology 1990; 40:1143.
60. Gonnering RS: Negative antibody response to long-term treatment of facial spasm with botulinum toxin. Am J Ophthalmol 1988; 105:313-315.
61. Gooch JE, Sandell TV: Botulinum toxin for spasticity and athetosis in children with cerebral palsy. Arch Phys Med Rehabil 1996; 77:508-511.
62. Greene P, Fahn S: Development of Antibodies to Botulinum Toxin Type A in Patients with Torticollis Treated with Injections of Botulinum Toxin Type A, in DasGupta BR (ed): Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects. New York, Plenum Press, 1993, pp 651-654.
63. Greene P, Fahn S, Diamond B: Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994; 9:213-217.
64. Greene PE, Fahn S: Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Mov Disord 1993; 8:479-483.
65. Greene PE, Fahn S: Response to botulinum toxin F in seronegative botulinum toxin A resistant patients. Mov Disord 1996; 11:181-184.
66. Gundersen CB: The effects of botulinum toxin on the synthesis, storage and release of acetylcholine. Prog Neurobiol 1980; 14:99-119.
67. Habermann E: 125-I-labeled neurotoxin from Clostridium botulinum A: preparation, binding to synaptosomes and ascent to the spinal cord. Naunyn Schmiedebergs Arch Pharmacol 1974; 281:47-56.
68. Hagenah R, Benecke R, Wiegand H: Effects of type A botulinum toxin on the cholmergic transmission at spinal Renshaw cells and on the inhibitory action at Ia inhibitory interneurones. Naunyn Schmiedebergs Arch Pharmacol 1977; 299:267-272.
69. Harris CP, Alderson K, Nebeker J, Holds JB, Anderson RL: Histologie features of human orbicularis oculi treated with botulinum A toxin. Arch Ophthdmol 1991; 109:393-395.
70. Hatheway CG, Dang C: Immunogenicity of the Neurotoxins of Clostridium botulinum, in Jankovic J, Hallertt M (eds): Therapy with Botulinum Toxin. New York, Marcel Dekker, 1994, pp 93-108.
71. Hatheway CH, Snyder JD, Seals JE, Edell TA, Lewis GE: Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A,B, and E. J Infect Dis 1984; 150:407-412.
72. Herrero BA, Ecklund AE, Street CS, Ford DF, King JK: Experimental botulism in monkeys: a clinical pathological study. Exp Mol Pathol 1967; 6:84-95.
73. Hughes R, Whaller BC: Influence of nerve ending activity and of drugs on the rate of paralysis of rat diaphragm preparations by Clostridium botulinum type A toxin. J Physiol 1962; 160:221-223.
74. Hutson RA, Collins MD, East AK, Thompson DE: Nucleotide sequence of the gene coding for nonproteolytic Clostridium botulinum type B neurotoxin comparison with other clostridial neurotoxins. Curr Microbiol 1994; 28:101-110.
75. Huttner WB: Snappy exocytoxins. Nature 1993; 365:104-105.
76. Jankovic J, Schwartz K: Response and immunoresistance to botulinum toxin injections. Neurology 1995; 45:1743-1746.
77. Kessler KR, Benecke R: The ebd test - a clinical test for the detection of antibodies to botulinum toxin type A. Mov Disord 1997; 12:95-99.
78. Koman LA, Mooney JF, 3rd, Smith BP, Goodman A, Mulvaney T: Management of spasticity in cerebral palsy with botulinum A toxin: report of a preliminary, randomized, double-blind trial. J Pediatr Orthop 1994; 14:299-303.
79. Koman LA, Mooney JF, III, Smith BP, Goodman A, Mulvaney T: Management of cerebral palsy with botulinum A toxin: preliminary investigation. J Pediatr Orthop 1993; 13:489-495.
80. Lamanna C, El Hage AN, Vick JA: Cardiac effects of botulinal toxin. Arch Int Pharmacodyn Ther 1988; 293:69-83.
81. Lange DJ: Systemic Effects of Botulinum Toxin, in Jankovic J, Hallett M (eds): Therapy with Botulinum Toxin. New York, Marcel Dekker, 1994, pp 109-118.
82. Lange DJ, Warner C, Brin MF, List T, Fahn S, Lovelace R: Botulinum toxin therapy: distant effects on neuromuscular transmission. Muscle Nerve 1985; 8:624 (Abstract).
83. Lew MF, Adornato BT, Duane DD, Dykstra DD, Factor SA, Massey JM, Brin MF, Jankovic J, Rodnitzky RL, Singer C, Swenson MR, Tarsy D, Murray JJ, Koller M, Wallace JD: Botulinum toxin type B (BotB): a double-blind, placebo-controlled, safely and efficacy study in cervical dystonia. Neurology 1997; 49(3):701-707.
84. Lorentz IT, Subramaniam SS, Yiannikas C: Treatment of idiopathic spasmodic torticollis with botulinum toxin A: a double-blind study on twenty-three patients. Mov Disord 1991; 6:145-150.
85. Ludlow CL, Hallett M, Rhew K, Cole R, Shimizu T, Sakaguchi G, Bagley JA, Schulz GM, Yin SG, Koda J: Therapeutic use of type F botulinum toxin [letter]. N Engl J Med 1992; 326:349-350.
86. Marsden CD: Botulinum toxin dangerous terminology errors reply. J R Soc Med 1993; 86:494.
87. Mclellan K, Das RE, Ekong TA, Sesardic D: Therapeutic botulinum type A toxin: factors affecting potency. Toxicon 1996; 34:975-985.
88. Mezaki T, Kaji R, Kimura J: Botulinum toxin trial for spasticity. Clin Neurol 1992; 32:637-638.
89. Mezaki T, Kaji R, Kohara N, Fujii H, Katayama M, Shimizu T, Kimura J, Brin MF: Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: a double-blind, controlled study. Neurology 1995; 45:506-508.
90. Mezaki T, Kaji R, Kohara N, Kimura J: Development of general weakness in a patient with amyotrophic lateral sclerosis after focal botulinum toxin injection. Neurology 1996; 46:845-846.
91. Montecucco C, Schiavo G: Structure and function of tetanus and botulinum neurotoxins. Q Rev Biophys 1995; 28:423-472.
92. Morante S, Furenlid L, Schiavo G, Tonello F, Zwilling R, Montecucco C: X-ray absorption spectroscopy study of zinc coordination in tetanus neurotoxin, astacin, alkaline protease and thermolysm. Eur J Biochem 1996; 235:606-612.
93. Monishi K, Koura M, Abe N, Fujii N, Fujinaga Y, lnoue K, Oguma K: Mosaic structures of neurotoxins produced from Clostridium botulinum types C and D organisms. Biochem Biophys Acta 1996; 1307:123-126.
94. Monishi K, Koura M, Fujii N, Fujinaga Y, Inoue K, Syuto B, Oguma K: Molecular cloning of the gene encoding the mosaic neurotoxin, composed of parts of botulinum neurotoxin types Cl and D, and PCR detection of this gene from Clostridium botulinum type C organisms. Appl Environ Wcrobiol 1996; 62:662-667.
95. Moser E, Ligon KM, Singer C, Sethi KD: Botulinum toxin A (Botox) therapy during pregnancy. Neurology 1997; 48:399 (Abstract).
96. Nagamine T, Kaji R, Hamano T, Kimura J: Treatment of focal dystonia with botulinum toxin. Clin Neurol 1991; 31:32-37.
97. Nathan P, Dimitrijevic MR, Sherwood AM: Reflex path length and clonus frequency [letter]. J Neurol Neurosurg Psychiatry 1985; 48:7-25
98. National Institutes of Health Consensus Development Conference: Clinical use of botulinum toxin. National Institutes of Health Consensus Development Statement, November 12 14, 1990. Arch Neurol 1991; 48:1294-1298.
99. Nebe A, Schelosky L, Wissel J. Ebersbach G, Scholz U, Poewe W: No effects on heart rate variability and cardiovascular reflex tests after botulinum toxin treatment of cervical dystonia [letter]. Mov Disord 1996; 11:337-339.
100. Paton JC, Lawrence AJ, Manson JI: Quantitation of Clostridium botulinum organisms and toxin in the feces of an infant with botulism. J Clin Microbiol 1982; 15:1-4.
101. Pearce LB, Borodic GE, Johnson EA, First ER, MacCallum R: The median paralysis unit: a more pharmacologically relevant unit of biologic activity for botulinum toxin. Toxicon 1995; 33:217-227.
102. Poewe W, Schelosky L, Kleedorfer B, Heinen F, Wagner M, Deuschl G: Treatment of spasmodic torticollis with local injections of botulinum toxin. One year follow up in 37 patients. J Neurol 1992; 239:21-25.
103. Poulet S, Hauser D, Quanz M, Niemann H, Popoff MR: Sequences of the botulinal neurotoxin E derived from Clostridium botulinum type E (strain Beluga) and Clostridium butyricum (strains ATCC 43181 and ATCC 43755). Biochem Biophys Res Commun 1992; 183:107-113.
104. Rhew K, Ludlow CL, Karp BI, Hallett M: Clinical Experience with Botulinum Toxin F, in Jankovic J, Hallett M (eds): Therapy with Botulinum Toxin. New York, Marcel Dekker, 1994, pp 323-328.
105. Russman BS, Tikon A, Gormley ME, Jr: Cerebral palsy: a rational approach to a treatment protocol, and the role of botulinum toxin in treatment. Muscle Nerve 1997; 20 (suppl 6): S181-S193.
106. Sampaio C: Brachial plexopathy after botulinum toxin administration for cervical dystonia reply. J Neural Neurosurg Psychiatry 1993; 56:1339.
107. Sanders DB, Massey EW, Buckley EC: EMG monitoring of botulinum toxin in blepharospasm. Neurology 1985; 35 (Suppl 1):272(Abstract).
108. Sanders DB, Massey EW, Buckley EG: Botulinum toxin for blepharospasm: single fiber EMG studies. Neurology 1986; 36:545-547.
109. Schantz EJ, Johnson EA: Dose standardisation of botulinum toxin [letter]. Lancet 1990; 335:421.
110. Schantz EJ, Johnson EA: Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 1992; 56:80-99.
111. Schantz EJ, Johnson EA: Preparation and Characterization of Botulinum Toxin Type A for Human Treatment, in Jankovic K, Hallet M (eds): Therapy with Botulinum Toxin. New York, Marcel Dekker, 1994, pp 41-49.
112. Schiavo G, Benfenati F, Poulain B, Rossetto O, Polverino de Eaureto P, DasGupta BR, Montecucco C: Tetanus and botulinum B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992; 359:832-835.
113. Schiavo G, Rossetto O, Santucci A, DasGupta BR, Montecucco C: Botulinum neurotoxins are zinc proteins. J Biol Chem 1992; 267:23479-23483.
114. Schiavo G. Rossetto O, Catsicas S, Delaureto PP, DasGupta BR, Benefenati F, Montecucco C: Identification of the nerve terminal targets of botulinum neurotoxin serotype-A, serotype-D, and serotype-E. J Biol Chem 1993; 268:23784-23787.
115. Schiavo G, Santucci A, DasGupta BR, Mehta PP, Jones J, Benefenati F, Wilson MC, Montecucco D: Botulinum neurotoxins serotypes A and E cleave Snap-25 at distinct COOH-terminal peptide bonds. FEBS Lett 1993; 335:99-103.
116. Schiavo G, Shone DD, Rossetto O, Alexander FCG, Montecucco CL: Botulinum neurotoxin serotype-F is a zinc endopeptidase specific for VAMP/synaptobrevin. J Biol Chem 1993; 268:11516-11519.
117. Schnider P, Brichta A, Schmied M, Auff E: Gallbladder dysfunction induced by botulinum A toxin [letter]. Lancet 1993; 342:811-812.
118. Scott AB: Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc 1981; 79:734-770.
119. Scott AB: Antitoxin reduces botulinurn side effects. Eye 1988; 2:29-32.
120. Scott AB: Clostridial toxins as therapeutic agents, in Simpson LL (ed): Botulinum Neurotoxin and Tetanus Toxin. New York, Academic Press, 1989, pp 399-412.
121. Scott AB, Suzuki D: Systemic toxtcity of botulinum toxin by intramuscular injection in the monkey. Mov Disord 1988; 3:333-335.
122. Sellin LC, Thesleff S: Pre- and post-synaptic actions of botulinum toxin at the rat neuromuscular junction. J Physiol 1981; 317:487-495.
123. Shaari CM, Sanders I: Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle Nerve 1993; 16:964-969.
124. Sheean GL, Lees AJ: Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A. J Neurol Neurosurg Psychiatry 1995; 59:601-607.
125. Siatkowski RM, Tyutyunikov A, Biglan AW, Scalise D, Genovese C, Raikow RB, Kennerdell J JS, Feuer WJ: Serum antibody production to botulinum A toxin. Ophthalmology 1993; 100:1861-1866.
126. Simpson LL: Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 1980; 212:16-21.
127. Simpson LL: Peripheral Actions of the Botulinum Toxins, in Simpson LL (ed): Botulinum Neurotoxin and Tetanus Toxin. New York, Academic Press, 1989, pp 153-178.
128. Simpson LL, DasGupta BR: Botulinum neurotoxin type E: studies on mechanism of action and on structure activity relationships. J Pharmacol Exp Ther 1983; 224:135-140.
129. Sloop RR, Cole BA, Escutin RO: Human response to botulinum toxin injection type B compared with type A. Neurology 1997; 49:189-194.
130. Spencer RF, McNeer KW: Botulinum toxin paralysis of adult monkey extraocular muscle. Structural alterations in orbital, singly innervated muscle fibers. Arch Ophthalmol 1987; 105:1703-1711.
131. Sunagawa H, Ohyama T, Watanabe T, Inoue K: The complete amino acid sequence of the Closiriiiium botulinum type D neurotoxin, deduced by nucleotide sequence analysis of the encoding phage d 16 phi genome. J Vet Med Sci 1992; 54:905-913.
132. Szabo EA, Pemberton JM, Desmarchelier PM: Detection of the genes encoding botulinum neurotoxin type A to type E by the polymerase chain reaction. Appl Environ Microbiol 1993; 59:3011-3020.
133. Tacket CO, Rogawski MA: Botulism, in Simpson LL (ed): Botulinum Neurotoxin and Tetanus Toxin. New York, Academic Press, 1989, pp 351-378.
134. Tonello F, Morante S, Rossetto O, Schiavo G, Montecucco C: Tetanus and botulism neurotoxins: a novel group of zinc endopeptidases. Adv Exp Med Biol 1996; 389:251-260.
135. Tsui JK, Wong NLM, Wong E, Calne DB: Production of circulating antibodies to botulinum A toxin in patients receiving repeated injections for dystonia. Ann Neurol 1988; 24:181(Abstract).
136. Tsui JKC, Hayward M, Mak EKM, Schulzer M: Botulinum toxin type B in the treatment of cervical dystonia: a pilot study. Neurology 1995; 45:2109-2110.
137. Tuite PJ, Lang AE: Severe and prolonged dysphagia complicating botulinum toxin A injections for dystonia in Machado-Joseph disease. Neurology 1996; 46:846.
138. Wall SA, Chait LA, Temlett JA, Perkins B, Hillen G, Becker P: Botulinum A chemodenervation: a new modality in cerebral palsied hands. Br J Plast Surg 1993; 46:703-706.
139. Wellhoner HH, Hensel B, Seib UC: Local tetanus in cats: neuropharmacokinetics of 125 I tetanus toxin. Naunyn Schmiedebergs Arch Pharmacol 1973; 276:375-386.
140. Wellhoner HH, Seib UC, Hensel B: Local tetanus in cats: the influence of neuromuscular activity on spinal distribution of 125-I-labeled tetanus toxin. Naunyn Schmiedebergs Arch Pharmacol 1973; 276:387-394.
141. Whelan SM, Elmore MJ, Bodsworth NJ, Atkinson T, Minton: The complete amino acid sequence of the Clostndium botulinum type E neurotoxin, derived by nucleotide sequence analysis of the encoding gene. Eur J Biochem 1992; 204:657-667.
142. Whelan SM, Elmore MJ, Bodsworth NJ, Brehm JK, Atkinson T, Minton NP: Molecular cloning of the Clostridium botulinum structural gene encoding the type B neurotoxin and determination of its entire nucleotide sequence. Appl Environ Microbiol 1992; 58:2345-2354.
143. Wiegand H, Erdmann G, Wellhoener HH: 125-I-labeled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol 1976; 292:161-165.
144. Wiegand H, Wellhoner HH: Proceedings: Type A botulinum toxin in cats: neural ascent and action on spinal cord reflexes. Naunyn Schmiedebergs Arch Pharmacol 1974; 282 (Suppl 282):R106.
145. Wiegand H, Wellhoner HH: The action of botulinum A neurotoxin on the inhibition by antidromic stimulation of the lumbar monosynaptic reflex. Naunyn Schmiedebergs Arch Pharmacol 1977; 298:235-238.
146. Willems A, East AK, Lawson PA, Collins MD: Sequence of the gene coding for the neurotoxin of Clostridium botulinum type A associated with infant botulism: comparison with other clostridial neurotoxins. Res Micmbiol 1993; 144:547-556.
147. Williams RS, Tse CK, Dolly JO, et al: Radioiodination of botulinum neurotoxin type A with retention of biological activity and its binding to brain-synaptosomes. Eur J Biochem 1983; 131:437-445.
148. Williamson LC, Halpern JL, Montecucco C, Brown JE, Neale EA: Clostridial neurotoxins and substrate proteolysis in intact neurons: botulinum neurotoxin C acts on synaptosomal-associated protein of 25 kda. J Biol Chem 1996; 271:7694-7699.
149. Wohlfarth G, Göschel H, Frevert J, Dengler R, Bigalke H: Botulinum A toxins: units versus units. Naunyn Schmiedebergs Arch Pharmacol 1997; 355(3):335-340.
150. Yamada S, Kuno Y, Iwanaga H: Effects of aminoglycoside antibiotics on the neuromuscular junction: Part I. Int J Clin Pharmacol Ther Toxicol 1986; 24:130-138.
151. Yamasaki S, Baumeister A, Blasi J, Link E, Comille F, Roques B, Fykse EM, Sudhof TC, Jahn R, Niemann H, Binz T: Cleavage of members of the synaptobrevin/VAMP family by types D and F botulinal neurotoxins and tetanus toxin. J Biol Chem 1994a; 269:12764-12772.
152. Yamasaki S, Hu YG, Binz T, Kalkuhl A, Kurazono H, Tamura T, Jahn R, Kandel E, Niemann H: Synaptobrevin/vesicle-associated membrane protein (VAMP) of Aplysia californica: structure and proteolysis by tetanus toxin and botulinal neurotoxins type D and F. Proc Natl Acad Sci USA 1994b; 91:4688-4692.
153. Zhou LQ, de Paiva A, Liu D, Aoki R, Dolly JO: Expression and purification of the light chain of botulinum neurotoxin A: a single mutation abolishes its cleavage of SNAP 25 and neurotoxicity after reconstitution with the heavy chain. Biochemistry 1995; 34:15175-15181.
154. Zuber M, Sebald M, Bathien N, Derecondo J, Rondot P: Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology 1993; 43:1715-1718.